CO6351715A2 - Daa-piridina como ligando del receptor periferico de benzodiazepina para el diagnostico por imagenes y para el tratamiento farmaceutico - Google Patents

Daa-piridina como ligando del receptor periferico de benzodiazepina para el diagnostico por imagenes y para el tratamiento farmaceutico

Info

Publication number
CO6351715A2
CO6351715A2 CO11013225A CO11013225A CO6351715A2 CO 6351715 A2 CO6351715 A2 CO 6351715A2 CO 11013225 A CO11013225 A CO 11013225A CO 11013225 A CO11013225 A CO 11013225A CO 6351715 A2 CO6351715 A2 CO 6351715A2
Authority
CO
Colombia
Prior art keywords
compounds
daa
compositions
diagnostic
agent
Prior art date
Application number
CO11013225A
Other languages
English (en)
Inventor
Lutz Lehmann
Andrea Thiele
Tobias Heinrich
Sonja Vollmer
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CO6351715A2 publication Critical patent/CO6351715A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nuclear Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se relaciona con compuestos de DAA-piridina de fórmula general I adecuados para marcar o ya marcados con 18F útiles como fármacos o como agentes de diagnóstico o como agentes de diagnóstico por imágenes, con métodos para preparar tales compuestos mediante síntesis en donde dichos compuestos se hacen reaccionar con un agente de fluoración con F, donde F = 18F o 19F, con composiciones que comprenden dichos compuestos en conjunto con vehículos o diluyentes aceptables farmacéuticamente, así como composiciones que comprenden un compuesto de la invención para su aplicación como agente de diagnóstico o agente de diagnóstico por imágenes, en particular para enfermedades del sistema nervioso central, con conjuntos de elementos que consisten de un vial sellado que contiene una cantidad predeterminada de dichos compuestos o composiciones, y con métodos para detectar la presencia del receptor periférico de benzodiacepinas (proteína translocadora) mediante tomografía de emisión de positrones (PET)Figura más representativa:
CO11013225A 2008-08-06 2011-02-04 Daa-piridina como ligando del receptor periferico de benzodiazepina para el diagnostico por imagenes y para el tratamiento farmaceutico CO6351715A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08161903 2008-08-06

Publications (1)

Publication Number Publication Date
CO6351715A2 true CO6351715A2 (es) 2011-12-20

Family

ID=41198601

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11013225A CO6351715A2 (es) 2008-08-06 2011-02-04 Daa-piridina como ligando del receptor periferico de benzodiazepina para el diagnostico por imagenes y para el tratamiento farmaceutico

Country Status (24)

Country Link
US (1) US20110200535A1 (es)
EP (1) EP2321279B1 (es)
JP (1) JP2011529929A (es)
KR (1) KR20110041559A (es)
CN (1) CN102112448B (es)
AR (1) AR073263A1 (es)
AU (1) AU2009278279B2 (es)
BR (1) BRPI0917099A2 (es)
CA (1) CA2733105A1 (es)
CL (1) CL2011000237A1 (es)
CO (1) CO6351715A2 (es)
CR (1) CR20110064A (es)
DO (1) DOP2011000046A (es)
EA (1) EA018650B1 (es)
EC (1) ECSP11010808A (es)
IL (1) IL210597A0 (es)
MX (1) MX2011001406A (es)
NZ (1) NZ590923A (es)
PE (1) PE20110226A1 (es)
SV (1) SV2011003830A (es)
TW (1) TW201010734A (es)
UY (1) UY32037A (es)
WO (2) WO2010015340A1 (es)
ZA (1) ZA201101700B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2114873E (pt) 2006-12-26 2013-05-06 Lantheus Medical Imaging Inc Ligandos para imagiologia de inervação cardíaca
WO2010015340A1 (en) * 2008-08-06 2010-02-11 Bayer Schering Pharma Aktiengesellschaft Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment
GB0904715D0 (en) 2009-03-19 2009-05-06 Ge Healthcare Ltd Aryloxyanilide derivataives
WO2011110488A1 (en) * 2010-03-09 2011-09-15 Bayer Pharma Aktiengesellschaft A novel pet imaging agent of amyloid plaques and its precursor
CA3041113C (en) * 2010-05-11 2022-01-18 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
CN103180318B (zh) 2010-05-14 2017-05-10 达那-法伯癌症研究所 雄性避孕组合物以及使用方法
WO2011143660A2 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
BR112012029005A2 (pt) 2010-05-14 2016-07-26 Dana Farber Cancer Inst Inc composições e métodos de tratamento de neoplasia, doença inflamatória e outros distúrbios
KR20190015765A (ko) 2011-09-09 2019-02-14 랜티우스 메디컬 이메징, 인크. 영상화제의 합성 및 사용을 위한 조성물, 방법 및 시스템
WO2015013635A2 (en) 2013-07-25 2015-01-29 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
CA2929652A1 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
RU2016134947A (ru) 2014-01-31 2018-03-01 Дана-Фарбер Кансер Институт, Инк. Производные диаминопиримидин бензолсульфона и их применение
JP2017504651A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体の使用
WO2015131113A1 (en) 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
JP2017525759A (ja) 2014-08-08 2017-09-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジヒドロプテリジノン誘導体およびその使用
RU2017104897A (ru) 2014-08-08 2018-09-10 Дана-Фарбер Кэнсер Инститьют, Инк. Производные диазепана и их применения
BR112017008714A2 (pt) 2014-10-27 2017-12-19 Tensha Therapeutics Inc inibidores de bromodomínio
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
US11306105B2 (en) 2015-09-11 2022-04-19 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
SG10202007099TA (en) 2015-09-11 2020-08-28 Dana Farber Cancer Inst Inc Acetamide thienotriazoldiazepines and uses thereof
CN114957291A (zh) 2015-11-25 2022-08-30 达纳-法伯癌症研究所股份有限公司 二价溴结构域抑制剂及其用途
CN105541931B (zh) * 2016-01-07 2018-08-17 江西师范大学 一种氟代糖苷衍生物及其制备方法
MA51199A (fr) * 2017-12-01 2020-10-07 UCB Biopharma SRL Agents d'imagerie
CN111039853B (zh) * 2019-12-26 2023-02-14 安徽大学 一种可用于光声成像和光热治疗的铁配合物及其制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU729000B2 (en) * 1997-08-04 2001-01-25 Nihon Nohyaku Co., Ltd. Aryloxyaniline derivatives
JP2000001476A (ja) * 1998-06-15 2000-01-07 Taisho Pharmaceut Co Ltd アリールオキシ含窒素アリールアミン誘導体
JP2004231647A (ja) * 2003-01-10 2004-08-19 Natl Inst Of Radiological Sciences フェニルオキシアニリン誘導体
US6870069B2 (en) * 2003-01-10 2005-03-22 National Institute Of Radiological Sciences Phenyloxyaniline derivatives
GB0329716D0 (en) * 2003-12-23 2004-01-28 Amersham Plc Radical trap
GB0407952D0 (en) * 2004-04-08 2004-05-12 Amersham Plc Fluoridation method
US8644910B2 (en) * 2005-07-19 2014-02-04 Biosensors International Group, Ltd. Imaging protocols
WO2007060517A1 (en) * 2005-11-22 2007-05-31 Ge Healthcare Limited 18f-labeled daa analogues and methods of labeling these analogues as positron emission tomography (pet) tracers for imaging peripheral benzodiazepine receptors
DE102005055524B4 (de) * 2005-11-22 2013-02-07 BEGO Bremer Goldschlägerei Wilh. Herbst GmbH & Co. KG Verfahren, Vorrichtung und System zur Herstellung eines keramischen Formkörpers
GB0525949D0 (en) * 2005-12-21 2006-02-01 Hammersmith Imanet Ltd Pet radiotracers
EP2029178B1 (en) * 2006-06-21 2012-03-14 GE Healthcare Limited Radiopharmaceutical products
WO2010015340A1 (en) * 2008-08-06 2010-02-11 Bayer Schering Pharma Aktiengesellschaft Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment

Also Published As

Publication number Publication date
WO2010015387A1 (en) 2010-02-11
DOP2011000046A (es) 2011-02-28
AU2009278279A1 (en) 2010-02-11
BRPI0917099A2 (pt) 2016-02-16
NZ590923A (en) 2012-12-21
MX2011001406A (es) 2011-03-21
UY32037A (es) 2010-03-26
SV2011003830A (es) 2011-05-20
PE20110226A1 (es) 2011-04-01
JP2011529929A (ja) 2011-12-15
WO2010015340A1 (en) 2010-02-11
CN102112448A (zh) 2011-06-29
EP2321279B1 (en) 2014-07-02
AU2009278279B2 (en) 2014-04-17
EA018650B1 (ru) 2013-09-30
CL2011000237A1 (es) 2011-07-29
TW201010734A (en) 2010-03-16
AR073263A1 (es) 2010-10-28
CR20110064A (es) 2011-03-30
EP2321279A1 (en) 2011-05-18
EA201100301A1 (ru) 2011-12-30
CA2733105A1 (en) 2010-02-11
US20110200535A1 (en) 2011-08-18
ECSP11010808A (es) 2011-03-31
CN102112448B (zh) 2014-08-06
KR20110041559A (ko) 2011-04-21
ZA201101700B (en) 2014-08-27
IL210597A0 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
CO6351715A2 (es) Daa-piridina como ligando del receptor periferico de benzodiazepina para el diagnostico por imagenes y para el tratamiento farmaceutico
CO2018005854A2 (es) Inhibidores de la proteína quinasa, método de preparación y uso médico de los mismos
ECSP099409A (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona, procedimientos para su preparación y su uso como agentes farmacéuticos
BR112016028345A2 (pt) composto, composição farmacêutica, métodos para inibir agregação de tau em um mamífero e para avaliar depósitos de tau em um paciente, e, uso de um composto.
DOP2010000263A (es) Derivados de imidazo-[1,2-b]-piridazina para el tratamiento de enfermedad mediada por cinasa de tirosina c-met
EA201490477A1 (ru) Фармацевтические составы, содержащие пропиленгликоль-гидрат дапаглифлозина
BRPI0711481A8 (pt) derivados radiomarcados de dihidrotetrabenzeno e seu uso como agente de imagens
CO6351689A2 (es) Formulaciones farmaceuticas que contienen ligandos de receptores de dopamina
WO2009052970A3 (en) Compounds for use in imaging, diagnosing, and/or treatment of diseases of the central nervous system or of tumors
CL2007003289A1 (es) Compuestos derivados de biciclocarboxiamida; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades provocadas por la hiperactivacion del receptor vc1 como dolor, enfermedad de vejiga, inflam
EP2607363A4 (en) CONDENSED RING COMPOUND FOR USE AS MINERALOCORTICOID RECEPTOR ANTAGONISTS
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
BRPI0905687A8 (pt) composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto
MY163136A (en) Peptide radiotracer compositions
EA201590797A1 (ru) Препараты с модифицированным высвобождением опрозомиба
WO2009143101A3 (en) Gastrin releasing peptide compounds
BRPI0917147B8 (pt) composto ou sal deste, uso de um composto ou sal deste, e, processo para fabricar um composto
Kawamura et al. Synthesis and evaluation of PET probes for the imaging of I2 imidazoline receptors in peripheral tissues
MX340487B (es) Compuestos para usarse en la formacion de imagenes, diagnostico y/o tratamiento de enfermedades del sistema nervioso central.
WO2010096426A3 (en) Compounds, compositions, methods of synthesis, and methods of treatment
CO6180495A2 (es) Formulacion de medicamento liquida
UY29848A1 (es) (1,3,4)-tiadiazol-2-il-amidas bicíclicas del ácido aril-sulfónico, procesos para su preparación y su uso como productos farmacéuticos
BRPI0606750A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e,composição farmacêutica
BR112013006498A2 (pt) composto
CU23842B1 (es) Derivados de n5-(2-etoxi-etil)-n3-(2-piridinil)-3,5-piperidin-dicarboxamida

Legal Events

Date Code Title Description
FC Application refused